Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study.

[1]  C. Chow,et al.  An improved method for the measurement of malondialdehyde in biological samples , 2006, Lipids.

[2]  L. Iuliano,et al.  Vitamin E Supplementation in Patients With Carotid Atherosclerosis: Reversal of Altered Oxidative Stress Status in Plasma but not in Plaque , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[3]  T. Hintze,et al.  Novel Vascular Biology of Third-Generation L-Type Calcium Channel Antagonists: Ancillary Actions of Amlodipine , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[4]  S. Hazen,et al.  Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways , 2003, Circulation.

[5]  L. Ghiadoni,et al.  Different Effect of Antihypertensive Drugs on Conduit Artery Endothelial Function , 2003, Hypertension.

[6]  J. Marrugat,et al.  High oxidative stress in patients with stable coronary heart disease. , 2003, Atherosclerosis.

[7]  M. Andreassi,et al.  Evidence for enhanced 8‐isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease , 2003, Coronary artery disease.

[8]  N. Cook,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events , 2003 .

[9]  S. Devaraj,et al.  Antioxidants and atherosclerosis: don't throw out the baby with the bath water. , 2003, Circulation.

[10]  J. Heinecke.  Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. , 2003, The American journal of cardiology.

[11]  S. Julius.  Lennart Hansson, MD , 2003 .

[12]  B. Fagerberg,et al.  Circulating Oxidized LDL Is Associated With Subclinical Atherosclerosis Development and Inflammatory Cytokines (AIR Study) , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[13]  D. Steinberg,et al.  Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis?: Do the Antioxidant Trials Conducted to Date Refute the Hypothesis? , 2002, Circulation.

[14]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[15]  R. Bach.  Heterogeneity of response to lipid-lowering therapy. , 2001, Journal of the American College of Cardiology.

[16]  R. Belardinelli,et al.  Oxidative stress and homocysteine in coronary artery disease. , 2001, Clinical chemistry.

[17]  T. Matsuo,et al.  Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes , 2001, Circulation.

[18]  J. Ross,et al.  Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. , 2001, Journal of the American College of Cardiology.

[19]  E. Eleuteri.  [Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[20]  S. L. Hazen,et al.  Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. , 2000, The Biochemical journal.

[21]  D. Steinberg,et al.  The oxidative modification hypothesis of atherogenesis: an overview. , 2000, Free radical biology & medicine.

[22]  G. FitzGerald,et al.  Indices of lipid peroxidation in vivo: strengths and limitations. , 2000, Free radical biology & medicine.

[23]  A. Passaro,et al.  Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production : key role of L-arginine availability. , 2000, Circulation.

[24]  D. Praticò.  F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. , 1999, Atherosclerosis.

[25]  P. Libby,et al.  Angiotensin induces inflammatory activation of human vascular smooth muscle cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[26]  M. Raftery,et al.  Increased plasma malondialdehyde levels in glomerular disease as determined by a fully validated HPLC method. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  J L Witztum,et al.  Oxidized phospholipids and isoprostanes in atherosclerosis. , 1998, Current opinion in lipidology.

[28]  R. Mason,et al.  Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. , 1998, Journal of lipid research.

[29]  J. Morrow,et al.  Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[30]  J. Morrow,et al.  Vascular superoxide dismutase deficiency impairs endothelial vasodilator function through direct inactivation of nitric oxide and increased lipid peroxidation. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[31]  C. Furberg,et al.  Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). , 1997, The American journal of cardiology.

[32]  Daniel Steinberg,et al.  Low Density Lipoprotein Oxidation and Its Pathobiological Significance* , 1997, The Journal of Biological Chemistry.

[33]  N. Ohte,et al.  Levels of thiobarbituric acid-reactive substance in plasma from coronary artery disease patients. , 1997, Clinical biochemistry.

[34]  T. Ozben,et al.  Serum and urine malondialdehyde levels in NIDDM patients with and without hyperlipidemia. , 1995, Free radical biology & medicine.

[35]  W. Sutherland,et al.  Lipid peroxidation of circulating low density lipoproteins with age, smoking and in peripheral vascular disease. , 1995, Atherosclerosis.

[36]  J. Jeng,et al.  Increased oxidizability of plasma low density lipoprotein from patients with coronary artery disease. , 1994, Biochimica et biophysica acta.

[37]  G. Parry,et al.  Age, sex, cigarette smoking and indices of free radical activity in healthy humans. , 1993, The European journal of medicine.

[38]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.

[39]  R. Mason,et al.  Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer. , 1992, Molecular pharmacology.

[40]  P. Canioni,et al.  Free and bound malondialdehyde measured as thiobarbituric acid adduct by HPLC in serum and plasma. , 1991, Clinical chemistry.

[41]  P. Odetti,et al.  Malondialdehyde (MDA) level in diabetic subjects. Relationship with blood glucose and glycosylated hemoglobin. , 1991, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[42]  A. J. Valente,et al.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Yalçın,et al.  Increased plasma and erythrocyte lipid peroxidation in hyperlipidemic individuals. , 1989, Atherosclerosis.

[44]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B. Hazenberg,et al.  The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. , 1988, Biochemical and biophysical research communications.

[46]  M. LeFree,et al.  Automated quantitative coronary arteriography: morphologic and physiologic validation in vivo of a rapid digital angiographic method. , 1987, Circulation.

[47]  P. Vanhoutte,et al.  Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. , 1986, The American journal of physiology.

[48]  V. Kakkar,et al.  Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia. , 1981, The American journal of medicine.

[49]  D. Richards,et al.  The lungs as receptor sites for cardiovascular regulation. , 1981, Circulation.